35 results about "Analogues/Derivatives" patented technology

This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of treating a subject suffering from a burn, or reducing the incidence of, or mitigating the severity of a burn in a subject, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound; 4) a method of treating a subject suffering from a spinal cord injury, by administering to the subject a selective androgen receptor modulator (SARM) and / or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.

This invention provides a method of treating androgen-deprivation induced osteoporosis, bone fractures or loss of bone mineral density (BMD) in a male human subject suffering from prostate cancer by administering a pharmaceutical composition comprising Toremifene and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, to the subject.

This invention provides a method of treatment, prevention, suppression, inhibition, or reduction of risk of developing androgen-deprivation induced skeletal-related events (SRE), such as pathologic fractures, surgery to bone, radiation to bone, spinal cord compression, change in antineoplastic therapy, including changes in hormonal therapy, new bone metastases, bone loss, or a combination thereof in men suffering from prostate cancer, comprising administering to a male subject suffering from prostate cancer a selective estrogen receptor modulator (SERM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

Formulations capable of extended or sustained release of high levels of caffeine or analogs, derivatives and metabolites thereof have been developed The formulations contain at least two components capable of releasing the caffeine or related compound differing rates to maintain a desired plasma level.

A method used for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and / or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and / or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In some embodiments, the invention may include methods for synthesizing chemical compounds including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues / derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.

The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and / or treatment of parasite infection (e.g., Plasmodium parasites) and / or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and / or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and / or salts thereof.

A method and system used for treating visual disabilities using carotenoids, carotenoid analogs, and / or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with visual disabilities may be thereby reduced. Analogs or derivatives of carotenoids may include substituents including for example co-antioxidants (e.g., Vitamin C and Vitamin C analogs). The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and / or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

This invention provides methods and compositions for inhibiting, reducing or slowing inflammatory diseases, for reducing sequestration or collecting or localization of macrophages, for treating a disease caused all or in part by or characterized by inflammation, for inhibiting, slowing, reversing or preventing atherosclerosis, and for increasing insulin sensitivity, decreasing or inhibiting resistance to insulin, or treating diabetes by inhibiting the biological activity of or antagonizing an axonal guidance protein. The method may feature administering a therapeutically effective amount of an agent to reduce or inhibit the biological activity of an axonal guidance protein or a receptor, analog, derivative or combination thereof.

The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a curcumin molecule or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent. In another embodiment, the present invention provides a method of treating cancer by administering a therapeutically effective amount of a composition comprising a micelle construct attached to curcumin or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent.

Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof.

A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock / resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD+), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor.Also disclosed are ex vivo and in vivo assay methods to test candidate compounds for activity, kits for carrying out the therapeutic methods or the assay methods of the invention and articles of manufacture that include compositions for use in the methods of the invention and instructions for the use thereof.

The invention provides polypeptides with the function of self-assembled potassium channel. The main sequence of polypeptides fragmentations, analog, derivative and variant amino acid of polypeptide possesses great than or equal to 70% of homology and great than or equal to 90% of similarity compared with the main sequence of the polypeptides amino acid. Polypeptides, nucleotide, polypeptide fragmentations, polypeptide analog, polypeptide derivatives and polypeptides variant are used for preparing the medicines which can treat diseases caused by potassium channel functional disorder / deficiency and hypertension, and also used for preparing tool drugs in the research field which can modify liposome and cell membrane potential. The invention provides a novel method for treating diseases caused by potassium channel functional disorder / deficiency and modifying cell membrane potential.

Compounds, methods, uses, compositions, kits and packages for the prevention and / or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and / or analogs, derivatives, pro-drugs, precursors thereof, and / or salts thereof, are described.

The invention discloses the application of berberine dimer analog derivatives in the preparation of medicines for preventing and treating Parkinson's disease. The structural formula of the berberine dimer analog derivative is shown in formula I. In the present invention, it is found that berberine dimer analogue derivatives or pharmaceutically acceptable salts thereof show better pharmacodynamic activity than the parent compound berberine on the in vitro cell model of Parkinson's disease, and it can obviously Improve the behavior of Parkinson's disease model mice, increase the number of dopaminergic neurons in the substantia nigra compacta, and increase the levels of dopamine and 3,4-dihydroxyphenylacetic acid in the striatum. Therefore, berberine dimer analog derivatives or pharmaceutically acceptable salts thereof can be made into related medicines for preventing and treating Parkinson's disease.

A pharmaceutical composition containing an anticancer compound, named isopicrinine, isolated from the plant Rhazya Stricta. The pharmaceutical composition may contain a salt, an analog, a derivative, and / or the prodrug of isopicrinine. A method of treating cancer with the pharmaceutical composition is disclosed. A method of extracting isopicrinine is also disclosed.